cdk4 6 Search Results


cdk4 6 inhibitors  (MedChemExpress)
94
MedChemExpress cdk4 6 inhibitors
Cdk4 6 Inhibitors, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4 6 inhibitors/product/MedChemExpress
Average 94 stars, based on 1 article reviews
cdk4 6 inhibitors - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
cdk4 6  (TargetMol)
94
TargetMol cdk4 6
Cdk4 6, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4 6/product/TargetMol
Average 94 stars, based on 1 article reviews
cdk4 6 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
cdk4 6 inhibitor iv  (Santa Cruz Biotechnology)
86
Santa Cruz Biotechnology cdk4 6 inhibitor iv
Cdk4 6 Inhibitor Iv, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4 6 inhibitor iv/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
cdk4 6 inhibitor iv - by Bioz Stars, 2026-04
86/100 stars
  Buy from Supplier
serine threonine kinase  (Santa Cruz Biotechnology)
94
Santa Cruz Biotechnology serine threonine kinase
Serine Threonine Kinase, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/serine threonine kinase/product/Santa Cruz Biotechnology
Average 94 stars, based on 1 article reviews
serine threonine kinase - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
cdk4 cdk6 inhibitor abemaciclib  (MedChemExpress)
94
MedChemExpress cdk4 cdk6 inhibitor abemaciclib
Cdk4 Cdk6 Inhibitor Abemaciclib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4 cdk6 inhibitor abemaciclib/product/MedChemExpress
Average 94 stars, based on 1 article reviews
cdk4 cdk6 inhibitor abemaciclib - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
abemaciclib  (TargetMol)
94
TargetMol abemaciclib
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Abemaciclib, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/abemaciclib/product/TargetMol
Average 94 stars, based on 1 article reviews
abemaciclib - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
cdk 4 6 inhibitor  (MedChemExpress)
92
MedChemExpress cdk 4 6 inhibitor
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Cdk 4 6 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk 4 6 inhibitor/product/MedChemExpress
Average 92 stars, based on 1 article reviews
cdk 4 6 inhibitor - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier
cdk4/6 inhibitors 2′-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′h-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one  (G1 Therapeutics)
90
G1 Therapeutics cdk4/6 inhibitors 2′-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′h-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Cdk4/6 Inhibitors 2′ ((5 (4 Methylpiperazin 1 Yl)Pyridin 2 Yl)Amino) 7′,8′ Dihydro 6′H Spiro[Cyclohexane 1,9′ Pyrazino[1′,2′:1,5]Pyrrolo[2,3 D]Pyrimidin] 6′ One, supplied by G1 Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4/6 inhibitors 2′-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′h-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one/product/G1 Therapeutics
Average 90 stars, based on 1 article reviews
cdk4/6 inhibitors 2′-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′h-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cdk4/6 inhibitors  (Bioscientifica Ltd)
90
Bioscientifica Ltd cdk4/6 inhibitors
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Cdk4/6 Inhibitors, supplied by Bioscientifica Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4/6 inhibitors/product/Bioscientifica Ltd
Average 90 stars, based on 1 article reviews
cdk4/6 inhibitors - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
compositions and methods for predicting response and resistance to cdk4/6 inhibition  (Cyclacel Inc)
90
Cyclacel Inc compositions and methods for predicting response and resistance to cdk4/6 inhibition
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Compositions And Methods For Predicting Response And Resistance To Cdk4/6 Inhibition, supplied by Cyclacel Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compositions and methods for predicting response and resistance to cdk4/6 inhibition/product/Cyclacel Inc
Average 90 stars, based on 1 article reviews
compositions and methods for predicting response and resistance to cdk4/6 inhibition - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cdk4/6 inhibitors in combination with xvir-n-31  (XVir Therapeutics GmbH)
90
XVir Therapeutics GmbH cdk4/6 inhibitors in combination with xvir-n-31
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Cdk4/6 Inhibitors In Combination With Xvir N 31, supplied by XVir Therapeutics GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4/6 inhibitors in combination with xvir-n-31/product/XVir Therapeutics GmbH
Average 90 stars, based on 1 article reviews
cdk4/6 inhibitors in combination with xvir-n-31 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cdk4/6-inhibitoren  (Anwendung GmbH)
90
Anwendung GmbH cdk4/6-inhibitoren
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Cdk4/6 Inhibitoren, supplied by Anwendung GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4/6-inhibitoren/product/Anwendung GmbH
Average 90 stars, based on 1 article reviews
cdk4/6-inhibitoren - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining abemaciclib, palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.

Journal: International Journal of Biological Sciences

Article Title: The Interaction of CircESR1 and HNRNPAB Regulates Cell Cycle Transition of Breast Cancer Cell

doi: 10.7150/ijbs.126014

Figure Lengend Snippet: Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining abemaciclib, palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.

Article Snippet: Tamoxifen (T6906), Fulvestrant (T2146), Abemaciclib (T2381), Palbociclib (T1785) and Ribociclib (T6199) were from Targetmol (Boston, USA).

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Control, MTT Assay, Transfection, Concentration Assay, Injection, Negative Control, Staining, Derivative Assay, Two Tailed Test